Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total transaction of $29,827.95. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Thursday, August 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The shares were sold at an average price of $197.00, for a total transaction of $316,973.00.
  • On Monday, July 3rd, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80.

Shares of Illumina, Inc. (NASDAQ ILMN) traded down 0.25% on Friday, hitting $209.68. 437,617 shares of the company traded hands. The company has a market capitalization of $30.61 billion, a PE ratio of 42.07 and a beta of 0.81. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $211.27. The stock’s 50-day moving average price is $192.45 and its 200-day moving average price is $178.64.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. Illumina’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.86 EPS. On average, equities analysts predict that Illumina, Inc. will post $3.65 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) SVP Sells $29,827.95 in Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/10/illumina-inc-ilmn-svp-sells-29827-95-in-stock.html.

A number of research firms have recently issued reports on ILMN. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective on the stock in a research note on Tuesday, May 23rd. Morgan Stanley reiterated an “underweight” rating and set a $115.00 price objective (up from $108.00) on shares of Illumina in a research note on Monday, May 15th. First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective on the stock in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $177.01.

A number of large investors have recently modified their holdings of ILMN. Nisa Investment Advisors LLC boosted its stake in Illumina by 41.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after purchasing an additional 1,800 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Illumina during the 1st quarter worth $212,000. Russell Investments Group Ltd. boosted its stake in Illumina by 83.4% during the 1st quarter. Russell Investments Group Ltd. now owns 125,997 shares of the life sciences company’s stock worth $21,502,000 after purchasing an additional 57,290 shares during the period. Canada Pension Plan Investment Board boosted its stake in Illumina by 80,307.7% during the 1st quarter. Canada Pension Plan Investment Board now owns 20,906 shares of the life sciences company’s stock worth $3,567,000 after purchasing an additional 20,880 shares during the period. Finally, Advisory Services Network LLC acquired a new stake in Illumina during the 1st quarter worth $117,000. Hedge funds and other institutional investors own 93.34% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.